UCB reports interim Phase II data for rozanolixizumab in thrombocytopenia

UCB S.A. (Euronext:UCB) reported interim data from 28 patients with primary persistent or chronic immune thrombocytopenia (ITP)

Read the full 177 word article

User Sign In